Literature DB >> 30915490

Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.

Christina Leitzen1, Timo Wilhelm-Buchstab2, Sabina Stumpf2, Martina Heimann2, David Koch2, Christopher Schmeel2, Birgit Simon2, Susanne Vornholt2, Stephan Garbe2, Fred Röhner2, Felix Schoroth2, Hans Heinz Schild2, Heinrich Schüller2, Thomas Müdder2.   

Abstract

PURPOSE: A planning study was performed for helical tomotherapy treatment. We evaluated the maximum achievable protection of organs at risk (OARs) in patients with malignant pleural mesothelioma after pleurectomy with simultaneous optimal target coverage.
MATERIALS AND METHODS: The datasets of 13 patients were included. The applied dose to the planning target volume (PTV) was 50.4 Gy with single doses of 1.8 Gy per fraction. Presuming optimal target coverage, we evaluated the applied dose to the OARs with special regard to the contralateral lung.
RESULTS: For left-(lsRT)/right(rsRT)-sided radiotherapy, target coverage for the PTV showed a D98 (mean) of 49.37/49.71 Gy (98.0%/98.6%) and a D2 (mean) of 54.19/54.61 Gy (107.5%/108.3%). The beam-on time was kept below 15 min. The achieved mean dose (D50) to the contralateral lung was kept below 4 Gy for lsRT and rsRT. With regard to the other organs at risk the applied doses were as follows: mean dose (lsRT): ipsilateral kidney (Dmean) 13.03 (5.32-22.18) Gy, contralateral kidney (Dmean) <2.0 Gy, heart (Dmean) 22.23 (13.57-27.72) Gy, spinal cord D1 <Gy; mean dose (rsRT): ipsilateral kidney (Dmean) 10.22 (6.30-18.04) Gy, contralateral kidney (Dmean) <2.1 Gy, heart (Dmean) 8.02 (6.0-10.38) Gy, spinal cord D1 <35.5 Gy.
CONCLUSION: With helical tomotherapy, postoperative treatment for malignant pleural mesothelioma after pleurectomy achieves good target coverage combined with simultaneous dose sparing to the (especially contralateral) OARs.

Entities:  

Keywords:  Dose constraints; IMRT; Pleural mesothelioma; Postoperative treatment; Sparing organs at risk

Mesh:

Year:  2019        PMID: 30915490     DOI: 10.1007/s00066-019-01458-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  20 in total

1.  Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues.

Authors:  Søren M Bentzen; Louis S Constine; Joseph O Deasy; Avi Eisbruch; Andrew Jackson; Lawrence B Marks; Randall K Ten Haken; Ellen D Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Novel radiation therapy approaches in malignant pleural mesothelioma.

Authors:  Andreas Rimner; Kenneth E Rosenzweig
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.

Authors:  Emilio Minatel; Marco Trovo; Jerry Polesel; Tania Baresic; Alessandra Bearz; Giovanni Franchin; Carlo Gobitti; Imad Abu Rumeileh; Annalisa Drigo; Paolo Fontana; Vittore Pagan; Mauro G Trovo
Journal:  Lung Cancer       Date:  2013-10-27       Impact factor: 5.705

Review 4.  The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer.

Authors:  Zhengfei Zhu; Xiaolong Fu
Journal:  Transl Lung Cancer Res       Date:  2015-06

5.  Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Takeshi Ebara; Hidemasa Kawamura; Takuya Kaminuma; Masahiko Okamoto; Daisaku Yoshida; Yu Okubo; Takeo Takahashi; Kunihiko Kobayashi; Hirozo Sakaguchi; Yoshitaka Ando; Takashi Nakano
Journal:  J Radiat Res       Date:  2012-02-25       Impact factor: 2.724

6.  Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study.

Authors:  Marta Scorsetti; Mario Bignardi; Alessandro Clivio; Luca Cozzi; Antonella Fogliata; Paola Lattuada; Pietro Mancosu; Piera Navarria; Giorgia Nicolini; Gaetano Urso; Eugenio Vanetti; Sabrina Vigorito; Armando Santoro
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

7.  PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.

Authors:  Andrei Fodor; Claudio Fiorino; Italo Dell'Oca; Sara Broggi; Marcella Pasetti; Giovanni Mauro Cattaneo; Luigi Gianolli; Riccardo Calandrino; Nadia Gisella Di Muzio
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

8.  Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.

Authors:  Kenneth E Rosenzweig; Marjorie G Zauderer; Benjamin Laser; Lee M Krug; Ellen Yorke; Camelia S Sima; Andreas Rimner; Raja Flores; Valerie Rusch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

9.  Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.

Authors:  William W Chance; David C Rice; Pamela K Allen; Anne S Tsao; Hiral P Fontanilla; Zhongxing Liao; Joe Y Chang; Chad Tang; Hubert Y Pan; James W Welsh; Reza J Mehran; Daniel R Gomez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-25       Impact factor: 7.038

10.  Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung.

Authors:  Emilio Minatel; Marco Trovo; Jerry Polesel; Imad Abu Rumeileh; Tania Baresic; Alessandra Bearz; Alessandro Del Conte; Giovanni Franchin; Carlo Gobitti; Annalisa Drigo; Andrea Dassie; Vittore Pagan; Mauro G Trovo
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

View more
  1 in total

1.  Dosimetric evaluation of helical tomotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma: a planning study for dose escalation.

Authors:  Fu-Li Zhang; Na Lu; Hua-Yong Jiang; Dian-Dian Chen; Ya-Di Wang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.